Witnesses for the hearing are:
Panel I
- The Honorable Howard A. Shelanski, Administrator, Office of Information and Regulatory Affairs
Panel II
- Dr. Douglas Holtz-Eakin, President, American Action Forum
Regulatory official grilled on consequences of ‘midnight’ rules
Jul 12th
From: The Hill
Rep. Tom Marino (R-Pa.) grilled President Obama’s top regulatory official Wednesday on what consequences there will be for federal agencies that try to rush through last-minute rules in the waning hours of the Obama administration.
Howard Shelanski, administrator of the Office of Information and Regulatory Affairs, issued a memo back in December advising the agencies to finish their highest priority rule-makings this summer to avoid a burst of “midnight regulations” before Obama leaves office.
OIRA Emphasizes Importance of Information (Data) Quality in Report to Congress
Jul 7th
OIRA 2015 Report to Congress on the Benefits and Costs of Federal Regulations and Agency Compliance with the Unfunded Mandates Reform Act contains an extensive discussion of the Data Quality Act. OIRA’s Report to Congress is thus a major improvement over the draft report which did not discuss the DQA. In addition to reporting on Requests for Correction and litigation seeking judicial review of agency DQA decisions, the OIRA Report emphasizes the Administration’s “Continuing Commitment to Information Quality” particularly with respect to science data.
Regulatory Reform Subcommittee to Hold Oversight Hearing on Implementation of Regulations
Jul 6th
From: House Judiciary Committee
White House Creation of a New Program to Accelerate Cancer Product Regulatory Review
Jul 1st
From: The White House
FACT SHEET: At Cancer Moonshot Summit, Vice President Biden Announces New Actions to Accelerate Progress Toward Ending Cancer As We Know It
***
Creation of a New Program to Accelerate Cancer Product Regulatory Review: The Food and Drug Administration (FDA) is excited to announce the hiring of Dr. Richard Pazdur as Acting Director of its new Oncology Center of Excellence (OCE). The OCE will unite cancer product regulatory review to enhance coordination and leverage the combined skills and clinical expertise across FDA centers. Under the Cancer Moonshot, the Acting Director is charged with accelerating the establishment of a program that brings together oncologists across the FDA in an effort to expedite the development of novel cancer-related drugs, biologics, and devices and support an integrated approach to tackling this devastating disease.
Out, out red tape: Congress weighs bills to reduce regulatory burden on academic science
Jun 29th
From: Science
***
Alexander’s board would have outside members, and it would have the ability to form panels to carry out studies. But unlike the academy’s recommendation it would serve an advisory role with the White House Office of Management and Budget (OMB). Given the committee’s jurisdiction, however, the bill would only affect researchers funded by NIH and other agencies within the Department of Health and Human Services.
Regulatory Information Service Center & OIRA Consolidated Information System (ROCIS): HOW TO Guide for Agency Users of the Information Collection Request (ICR) Module
Jun 14th
Editor’s Note: The complete ROCIS HOW TO Guide for Agency Users of the Information Collection Request (ICR) Module (June 9, 2016) is attached here (pdf). Below is a noteworthy excerpt.
From: GSA/Regulatory Information Service Center
Appendix A: Disaggregating Information Collection Requests (ICRs) into Information Collections (ICs): Questions and Answers
***
- Why is OMB requiring that information collection requests (ICRs) be divided into information collections (ICs)?
Revisiting the Appropriate Use of Agency Regulatory Guidance
Jun 8th
From: US Senate Committee on Homeland Security & Government Affairs
Subcommittee on Regulatory Affairs and Federal Management
June 09, 2016 11:15AM
Agenda
This hearing will build on the Subcommittee’s previous guidance hearing held September 23, 2015, titled “Examining the Use of Agency Regulatory Guidance.” Topics for the hearing may include a discussion on lingering concerns and developments arising from specific problematic guidance documents; agency initiatives to address U.S. Government Accountability Office (GAO) recommendations on internal controls for good guidance practices; and a discussion of the role of the Office of Information and Regulatory Affairs (OIRA) in advising and implementing its cross-government good guidance practices.
Regulatory Agenda Published for Obama’s Last Year
May 19th
From: Bloomberg/BNA Daily Report for Executives
By Cheryl Bolen
May 18 — All the rules that are expected to be acted on in the remainder of the Obama administration are now published in the Spring 2016 Unified Agenda of Federal Regulatory and Deregulatory Actions.
***
Final Agenda in Fall
The complete Spring 2016 unified agenda lists regulations by agency.
A Conversation with OIRA Administrator Shelanski on International Regulatory Cooperation with Canada
May 9th
From: The White House
by Emily Cain
Summary: Leading up to the U.S.- Canada RCC Meetings on May 4-5, OIRA Administrator Howard Shelanski provides his take on the future of international regulatory cooperation.
[White House] Editor’s Note: Leading up to the U.S.-Canada Regulatory Cooperation Council (RCC) Meetings on May 4-5, I sat down with Howard Shelanski, Administrator of the Office of Information and Regulatory Affairs (OIRA) at the Office of Management and Budget, to discuss the importance of international regulatory cooperation and provide his take on the future of the U.S. – Canada RCC. A summary of the conversation is below.
Advocacy Economists participate in the annual Society for Benefit-Cost Analysis Conference
Apr 5th
From: Office of Advocacy | Small Business Administration
By Michael McManus, Regulatory Research Fellow
Late last week the SBA Office of Advocacy participated in the annual Society for Benefit-Cost Analysis Conference. The conference, widely attended by government employees and academics alike, works to improve the theory and practice of benefit-cost analysis.
***
Office of Advocacy economists Patrick Delehanty and Lindsay Scherber chaired a roundtable discussion focused on how agencies currently analyze the effects of regulations on small businesses and potential improvements to the process. Advocacy regulatory economist Jonathan Porat was joined by senior economists from the Consumer Finance Protection Bureau, Federal Drug Administration and the White House’s Office of Management and Budget.